Pasithea Therapeutics Corp.（以下简称"Pasithea"）宣布，其研发的药物Pas-004已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该药物旨在治疗I型神经纤维瘤病（Nf1）相关的丛状神经纤维瘤（Pn），此类肿瘤可导致显著的发病率和严重健康问题。
快速通道资格的授予将加速Pas-004的研发和审评进程，为患者提供更早获得创新疗法的可能。
Pasithea Therapeutics Corp.（以下简称"Pasithea"）宣布，其研发的药物Pas-004已获得美国食品药品监督管理局（FDA）授予的快速通道资格。该药物旨在治疗I型神经纤维瘤病（Nf1）相关的丛状神经纤维瘤（Pn），此类肿瘤可导致显著的发病率和严重健康问题。
快速通道资格的授予将加速Pas-004的研发和审评进程，为患者提供更早获得创新疗法的可能。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.